• Pharma Regulatory Services in Ireland

    Overview

    Despite a moderate growth value, consistent demand for medicinal products has made Ireland a viable market for drug and biological products. Before marketing medicinal products in the country, manufacturers must obtain an approval from the Health Products Regulatory Authority (HPRA) of Ireland by submitting a Marketing Authorization Application (MAA). As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Pharma Regulatory Services in Denmark

    Overview

    Denmark is highly regarded for its thriving pharmaceutical market. All medicinal products to be marketed in the country must be approved by the Danish Medicines Agency before marketing them locally. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Pharma Regulatory Services in Czech Republic

    Overview

    Market for drugs and biological products in Czech Republic is catching up with global demand. Prior to marketing their products in market, the pharmaceutical product manufacturers must obtain approval from the State Institute for Drug Control of Czech Republic by submitting a Marketing Authorization Application (MAA). As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Pharma Regulatory Services in Belgium

    Overview

    Belgium is an economically developed nation with due credit to its industrial progress and huge healthcare spends. Drug and biological products must be authorized by the Federal Agency for Medicines and Health Products before distribution and marketing for human use in Belgium. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Pharma Regulatory Services in Austria

    Overview

    Austrian government’s healthcare expenditure clearly showcases good market for drug/medicinal products in the country. Aging population and increased health awareness among Austrians are major reasons behind the surging demand for pharmaceutical products. Prior to marketing medicinal products locally, manufacturers must obtain a Market Authorization approved by the Austrian Agency for Health and Food Safety. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Pharma Regulatory Services in Germany

    Overview

    Pharmaceutical market in Germany has displayed a continued growth over the years. As a prominent member of European Union (EU), Germany requires a Market Authorization (MA) granted by the country’s Ministry of Health (MoH) to market and distribute medicinal products locally. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:

  • Pharma Regulatory Services in France

    Overview

    With advance healthcare provisions in place, market forecast for pharmaceuticals in France predicts a continued demand. For a medicinal product / drug to be marketed in France, a manufacturer must obtain a Marketing Authorization (MA) from the Ministry of Health (MoH) of France. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:

  • Regulatory Services in Norway

    Overview

    Emerging as a strong provider of transitional medicines, the momentum turn towards Norway for investments in medicines and medical devices. To enter the market, manufacturers must obtain market authorizations from the Norwegian Medicines Agency (NOMA), the agency regulating the registrations and licenses. With the complex Regulatory requirements, foreign manufacturers might face certain Regulatory procedural challenges while approaching for necessary market authorizations.

  • Regulatory Services in Belarus

    Overview

    With growing importance for modernization and with increased government spending towards healthcare, Belarus offers a good bet of business opportunities for foreign medicinal products / medical device manufacturers. To get the market entry, manufacturers must obtain market authorizations from the Ministry of Health, the authority which regulates respective Regulatory activities in the region. For foreign manufacturers, navigating the Belarusian Regulatory regime might stand a challenging aspect for obtaining necessary registrations and approvals.